LXRX

Lexicon Pharmaceuticals, Inc. (LXRX) | Rumor.io

Lexicon Pharmaceuticals

LXRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,514

Bullish sentiment (50-day avg)69%

Price to earnings ratio-13.5

Market capitalization845.4M

Earnings per share-0.16

Dividend yield (TTM)—

Revenue (annual)49.8M

Net income (annual)-50.3M

Social

What share of all stock conversation is about LXRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Sep 28

Cantor Fitzgerald initiated coverage of Lexicon Pharmaceuticals with an Overweight rating and a $8.00 price target, implying substantial upside from recent levels.
The analyst based the view on Lexicon's late-stage cardiovascular program, particularly the Phase 3 SONATA-HCM trial evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM), with preliminary data expected in Q1 2027.
The combination of new analyst coverage, a completed pivotal trial, and an expected 2027 data catalyst helped drive the stock higher despite broad market pressure.

Generated by AI

Sentiment

Of the messages about LXRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5% -15.28	55% -33	66.67% -4.08	86.02% +3.85
Bearish	37.5% +15.28	45% +33	33.33% +4.08	13.98% -3.85

Bullish· Jun 26

Lexicon Pharmaceuticals, Inc. ($LXRX) has broken through a previous resistance level, indicating a new wave of upward momentum.
The stock has seen significant short covering, with some investors taking massive positions, suggesting a bullish sentiment among market participants.
$LXRX has reached a new 52-week high, with trading volume exceeding 30 million shares, indicating strong investor interest and a potentially undervalued stock.

Bearish· Jun 11

The company's management is incompetent and lacking in transparency.
The FDA is unlikely to approve Zynquista based on the Steno1 study, which has limitations and cannot be replicated in the US.
The company's statements about near-term FDA decisions and positive news are likely false and intended to manipulate investors.

Generated by AI

Topics

Of the messages about LXRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	19.67%	50%	52.44%
Technical Analysis	0%	6.56%	7.41%	24.07%
Analysts	48.39%	47.54%	27.78%	10.59%
Earnings	0%	0%	0%	9.42%
Macro	48.39%	24.59%	13.89%	1.59%
Controversies	3.23%	1.64%	0.93%	1.88%

Earnings· Apr 27

Lexicon Pharmaceuticals (LXRX) reported Q1 loss per share of $0.63, beating the estimated loss of $0.69.
The company's revenue of $7.999M exceeded the estimated $7.790M.
Lexicon's Q1 earnings beat the Estimize EPS consensus by 1c and the Estimize Revenue consensus by $0.13M.

Analysts· Jan 29

JP Morgan upgraded Lexicon Pharmaceuticals to Neutral with a price target of $7.
Wedbush downgraded Lexicon Pharmaceuticals to Neutral with a price target of $8.
Analysts are divided on Lexicon Pharmaceuticals, with some upgrading and others downgrading the stock, highlighting the uncertainty surrounding the company's future performance.

Announcements· Mar 23

Lexicon Pharmaceuticals (LXRX) and Novo Nordisk announced the initiation of a Phase 1 study for LX9851, an oral non-incretin candidate for obesity and related metabolic disorders.
The study will evaluate the safety and tolerability of LX9851 in 96 subjects and is expected to complete in Q1 2027.
Lexicon earned a second $10 million milestone payment from Novo Nordisk, with the potential for a third payment this year and up to $1.3 billion in total payments plus tiered royalties.

Technical Analysis· Mar 28

$LXRX is forming a falling wedge, indicating a potential breakout.
The stock has strong support at $0.59 and needs to break above $0.66 to ensure a bull run.
The RSI is heavily oversold at 26, suggesting a potential reversal and a possible break to a new high.

Generated by AI

Community

Of the messages about LXRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	41.38%	84%	90%	88.28%
Newcomers	58.62%	16%	10%	11.72%

Regulars· Sep 28

The Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with an Overweight rating and a $8.00 price target, based on the company's late-stage cardiovascular program and the Phase 3 SONATA-HCM trial evaluating sotagliflozin.
The SONATA-HCM trial has completed enrollment, exceeding its original target of 500 patients across more than 130 sites in 20 countries, with preliminary data expected in the first quarter of 2027, providing a potential catalyst for the stock.
The combination of new analyst coverage, a completed pivotal trial, and an expected 2027 data catalyst has driven the stock higher, despite broad market pressure, with some participants noting a significant increase in trading volume and a notable price increase.

Newcomers· Jun 27

This newcomer is shifting their focus from tech stocks to pharma, citing high valuation concerns in tech.
They mention $LXRX as a potential pick, suggesting a specific interest in Lexicon Pharmaceuticals.
The newcomer's investment strategy is adapting to changing market sentiment, with a focus on pharma as the next wave of growth.

Generated by AI

News

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today | The Motley Fool

An analyst at a prominent research firm initiated coverage of the

1d agofool.com

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

Cantor starts Lexicon at overweight with an $8 price target. Read more here.

1d agoSeeking Alpha

Why is Lexicon Pharmaceuticals stock surging today?

1d agoInvesting.com

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

1d agoInvesting.com

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mo

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

2d agoBenzinga

Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight

2d agoInvesting.com

Also Discussed

Investors talking about LXRX also mention

#	Name	Attention
1	Cullinan Therapeutics Inc.CGEM	0%new
2	Spyre Therapeutics, Inc.SYRE	0%new
3	Emergent BioSolutions Inc.EBS	0%new
4	Exelixis Inc.EXEL	0%-0.03
5	Sanofi ADRSNY	0%-0.01
6	Mativ Holdings Inc.MATV	0%new
7	Kymera Therapeutics Inc.KYMR	0%0
8	Arcus Biosciences, Inc.RCUS	0%new
9	Nurix Therapeutics, Inc.NRIX	0%new
10	Invesco Semiconductors ETFPSI	0%0

Lexicon Pharmaceuticals, Inc.

Healthcare
Biotechnology

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.

Website

Location

2445 Technology Forest Boulevard

The Woodlands, TX, 77381

United States

Social

What share of all stock conversation is about LXRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Sep 28

Cantor Fitzgerald initiated coverage of Lexicon Pharmaceuticals with an Overweight rating and a $8.00 price target, implying substantial upside from recent levels.
The analyst based the view on Lexicon's late-stage cardiovascular program, particularly the Phase 3 SONATA-HCM trial evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM), with preliminary data expected in Q1 2027.
The combination of new analyst coverage, a completed pivotal trial, and an expected 2027 data catalyst helped drive the stock higher despite broad market pressure.

Generated by AI

Sentiment

Of the messages about LXRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5% -15.28	55% -33	66.67% -4.08	86.02% +3.85
Bearish	37.5% +15.28	45% +33	33.33% +4.08	13.98% -3.85

Bullish· Jun 26

Lexicon Pharmaceuticals, Inc. ($LXRX) has broken through a previous resistance level, indicating a new wave of upward momentum.
The stock has seen significant short covering, with some investors taking massive positions, suggesting a bullish sentiment among market participants.
$LXRX has reached a new 52-week high, with trading volume exceeding 30 million shares, indicating strong investor interest and a potentially undervalued stock.

Bearish· Jun 11

The company's management is incompetent and lacking in transparency.
The FDA is unlikely to approve Zynquista based on the Steno1 study, which has limitations and cannot be replicated in the US.
The company's statements about near-term FDA decisions and positive news are likely false and intended to manipulate investors.

Generated by AI

Topics

Of the messages about LXRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	19.67%	50%	52.44%
Technical Analysis	0%	6.56%	7.41%	24.07%
Analysts	48.39%	47.54%	27.78%	10.59%
Earnings	0%	0%	0%	9.42%
Macro	48.39%	24.59%	13.89%	1.59%
Controversies	3.23%	1.64%	0.93%	1.88%

Earnings· Apr 27

Lexicon Pharmaceuticals (LXRX) reported Q1 loss per share of $0.63, beating the estimated loss of $0.69.
The company's revenue of $7.999M exceeded the estimated $7.790M.
Lexicon's Q1 earnings beat the Estimize EPS consensus by 1c and the Estimize Revenue consensus by $0.13M.

Analysts· Jan 29

JP Morgan upgraded Lexicon Pharmaceuticals to Neutral with a price target of $7.
Wedbush downgraded Lexicon Pharmaceuticals to Neutral with a price target of $8.
Analysts are divided on Lexicon Pharmaceuticals, with some upgrading and others downgrading the stock, highlighting the uncertainty surrounding the company's future performance.

Announcements· Mar 23

Lexicon Pharmaceuticals (LXRX) and Novo Nordisk announced the initiation of a Phase 1 study for LX9851, an oral non-incretin candidate for obesity and related metabolic disorders.
The study will evaluate the safety and tolerability of LX9851 in 96 subjects and is expected to complete in Q1 2027.
Lexicon earned a second $10 million milestone payment from Novo Nordisk, with the potential for a third payment this year and up to $1.3 billion in total payments plus tiered royalties.

Technical Analysis· Mar 28

$LXRX is forming a falling wedge, indicating a potential breakout.
The stock has strong support at $0.59 and needs to break above $0.66 to ensure a bull run.
The RSI is heavily oversold at 26, suggesting a potential reversal and a possible break to a new high.

Generated by AI

Community

Of the messages about LXRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	41.38%	84%	90%	88.28%
Newcomers	58.62%	16%	10%	11.72%

Regulars· Sep 28

The Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with an Overweight rating and a $8.00 price target, based on the company's late-stage cardiovascular program and the Phase 3 SONATA-HCM trial evaluating sotagliflozin.
The SONATA-HCM trial has completed enrollment, exceeding its original target of 500 patients across more than 130 sites in 20 countries, with preliminary data expected in the first quarter of 2027, providing a potential catalyst for the stock.
The combination of new analyst coverage, a completed pivotal trial, and an expected 2027 data catalyst has driven the stock higher, despite broad market pressure, with some participants noting a significant increase in trading volume and a notable price increase.

Newcomers· Jun 27

This newcomer is shifting their focus from tech stocks to pharma, citing high valuation concerns in tech.
They mention $LXRX as a potential pick, suggesting a specific interest in Lexicon Pharmaceuticals.
The newcomer's investment strategy is adapting to changing market sentiment, with a focus on pharma as the next wave of growth.

Generated by AI

Lexicon Pharmaceuticals

Social

Sep 28

Bullish· Jun 26

Bearish· Jun 11

Earnings· Apr 27

Analysts· Jan 29

Announcements· Mar 23

Technical Analysis· Mar 28

Regulars· Sep 28

Newcomers· Jun 27

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today | The Motley Fool

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

Why is Lexicon Pharmaceuticals stock surging today?

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mo

Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight

Also Discussed

Lexicon Pharmaceuticals, Inc.

Company Information

Location

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today | The Motley Fool

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

Why is Lexicon Pharmaceuticals stock surging today?

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mo

Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight

Also Discussed

Social

Sep 28

Bullish· Jun 26

Bearish· Jun 11

Earnings· Apr 27

Analysts· Jan 29

Announcements· Mar 23

Technical Analysis· Mar 28

Regulars· Sep 28

Newcomers· Jun 27